ArticleEuropean journal of clinical pharmacology2025
Meningioma in users of progestogen contraceptives: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS).
Article in European journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-world and computational identification of herbal candidates associated with adverse event patterns in glucagon-like peptide-1 therapy for obesity.Scientific reports · 2026Article
- Medical Treatment for Endometriosis: One Size Does Not Fit All.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRecent observational studies have suggested certain progestogens used for contraception may increase the risk of intracranial meningioma. This study analyzed meningioma reporting among females to the US Food and Drug Administration Adverse Event Reporting System (FAERS) across all progestogen-based contraceptives currently approved in the USA.
methodsDisproportionality analysis was performed using individual case safety reports (ICSRs) submitted to FAERS (second quarter of 2016-first quarter of 2024) involving nine progestogens approved for contraception in the US. Eleven Medical Dictionary for Regulatory Activities (MedDRA) preferred terms classified meningioma cases. Crude and adjusted reporting odds ratios (RORs) and 95% confidence intervals (CIs) were estimated using logistic regression. A lower 95% CI > 1.0 and ≥ 3 meningioma cases constituted a disproportionality signal.
resultsDuring the study period, progestogen contraceptives were reported in 136,654 ICSRs and 283 meningioma cases involving females. Seven progestogens exhibited positive meningioma disproportionality signals in univariable analyses. In multivariable models adjusting for age, weight, use of any medication for contraception, number of associated drug-event pairs, reporter country, and reporter occupation, potential meningioma signals were detected for desogestrel (ROR 2.22; 95% CI 1.29-3.83), levonorgestrel (ROR 3.21; 95% CI 2.11-4.86), and medroxyprogesterone acetate (ROR 4.01; 95% CI 2.10-7.66). Meningioma disproportionality signals for levonorgestrel and medroxyprogesterone acetate persisted through several sensitivity analyses.
conclusionNotwithstanding the important limitations of disproportionality analyses, these findings add to a growing body of literature describing a potential association between progestogen-based contraceptives and meningioma. Screening should be recommended for progestogen-treated females experiencing symptoms consistent with meningioma.
Indexed as
Identifiers
40824302What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.